Code of Vermont Rules › Agency 13 - AGENCY OF HUMAN SERVICES › Sub-Agency 140 - DEPARTMENT OF HEALTH › Chapter 062 - MEDICATION-ASSISTED THERAPY FOR OPIOID DEPENDENCE FOR: 1. OFFICE-BASED OPIOID TREATMENT (OBOT) PROVIDERS PRESCRIBING BUPRENORPHINE; 2. OPIOID TREATMENT PROVIDERS (OTP) › Section 13 140 062 - MEDICATION-ASSISTED THERAPY FOR OPIOID DEPENDENCE FOR: 1. OFFICE-BASED OPIOID TREATMENT (OBOT) PROVIDERS PRESCRIBING BUPRENORPHINE; 2. OPIOID TREATMENT PROVIDERS (OTP)

Current through June, 2024
Section 1.0 Authority.
This rule is established pursuant to
				  18 V.S.A.
				  §
											4752.
Section 2.0 Purpose.
This rule establishes minimum requirements for Office Based
				  Opioid Treatment (OBOT) providers to prescribe, and in defined circumstances,
				  dispense medication to patients accessing treatment for opioid use disorder.
				  The rule also establishes Vermont-specific requirements for Opioid Treatment
				  Programs (OTPs) that are in addition to the requirements of 42 CFR Part
				  8.
Section 3.0 Definitions.
3.1 "Administrative Discharge" means the
				process of a patient separating from an OBOT provider for
				non-compliance/cause.
3.2
				"Continuity of Care Plan Checklist" means the Department-published Continuity
				of Care Plan checklist.
3.3 "DEA"
				means the Drug Enforcement Administration in the U.S. Department of
				Justice.
3.4 "DEA Number" means the
				Drug Enforcement Administration number assigned to each provider granting the
				provider authority to prescribe controlled substances.
3.5 "Department" means the Vermont Department
				of Health.
3.6 "Diversion" means
				the illegal use of a prescribed controlled substance for a use other than the
				use for which the substance was prescribed.
3.7 "Eligible MOUD Provider" means a
				Vermont-licensed provider with a valid DEA number.
3.8 "Informed consent" means agreement by a
				patient to a medical procedure, or for participation in a medical intervention
				program, after achieving an understanding of the relevant medical facts,
				benefits, and the risks involved.
3.9 "Maintenance Treatment" means MOUD
				lasting longer than one year.
3.10
				"Medication for Opioid Use Disorder," or "MOUD" means medications used to treat
				opioid use disorder such as methadone, buprenorphine, and naltrexone.
3.11 "Medication Unit" means a facility that
				has been established as part of, but is geographically separate from, an opioid
				treatment program (OTP) from which eligible MOUD providers dispense or
				administer medications used to treat opioid use disorder and/or collect samples
				for drug testing or analysis. A Medication Unit is regulated pursuant to 42 CFR
				Part 8.
3.12 "Office Based Opioid
				Treatment provider" and "OBOT provider" means a provider that prescribes MOUD
				pursuant to federal and State law, federal regulations, and State rules, and
				that is not an OTP. An OBOT may be a preferred provider, a specialty addiction
				practice, an individual provider practice or several providers practicing as a
				group.
3.13 "Opioid Treatment
				Program" and "OTP" means a program or practitioner registered under
				21 U.S.C.
				823(g)(1) engaged in
				treatment of individuals with OUD. OTPs are specialty treatment programs for
				dispensing medication, including methadone and buprenorphine to treat opioid
				use disorder, under controlled and observed conditions. OTPs offer onsite
				ancillary services.
3.14
				"Physician" means a licensed medical doctor or a licensed doctor of osteopathy
				as defined in 26 V.S.A. Ch. 23, Subchapter 3.
3.15 "Preferred provider" means an entity
				that has attained a certificate from the Department and has an existing
				contract or grant from the Department to provide treatment for substance use
				disorder.
3.16 "Provider" means a
				health care provider as defined by
				18 V.S.A.
				§
											9402.
3.17 "Psychosocial Assessment" means an
				evaluation of the psychological and social factors that are experienced by an
				individual or family as the result of addiction. These factors may complicate
				an individual's recovery or act as assets to recovery.
3.18 "Telehealth" means methods for
				healthcare service delivery using telecommunications technologies. Telehealth
				includes telemedicine, store and forward, and telemonitoring.
3.19 "Treatment Agreement" means a document
				outlining the responsibilities and expectations of the OBOT provider and the
				patient that is signed and dated by the patient.
3.20 "Toxicology specimens" means urine, oral
				mucosa, or serum blood that will be tested for the purpose of detecting the
				presence of alcohol and/or various scheduled drugs.
3.21 "VPMS" means the Vermont Prescription
				Monitoring System, the electronic database that collects data on Schedule II,
				III, or IV controlled substances dispensed in Vermont.